RET Inhibitor
PreclinicalSmall molecule
RET Inhibitor is one of 49 small molecule programs targeting Thyroid Cancer. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Thyroid Cancer
#DrugCompanyPhaseTrials
1Lenvima
EisaiApproved
Tafinlar
NovartisApproved
Keytruda
Merck & Co.Approved
Cabometyx
Bristol-Myers SquibbApproved
Mekinist
NovartisApproved
Retevmo
Eli LillyApproved
Vitrakvi
BayerApproved
Gemzar
Johnson & JohnsonApproved
Nexavar
BayerPhase 3
Gavreto
RRigel Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RET Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- FFudan University